Literature DB >> 28605303

Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients.

Tania Pilli1, Silvia Cantara1, Carlotta Marzocchi1, Sandro Cardinale1, Chiara Santini1, Gabriele Cevenini2, Furio Pacini1.   

Abstract

BACKGROUND: It has recently been demonstrated that the combination of miRNA-190 and -95 (expressed as probability of malignant risk: pmiRNA) in the serum of Caucasian patients with thyroid nodular disease allows the identification of nodules at high risk of malignancy with great accuracy. The present study aimed to validate these results in a larger cohort of patients.
MATERIALS AND METHODS: This study prospectively analyzed 1000 patients. Cytological diagnosis was available in 982/1000 (98.2%) and histological diagnosis in 445/1000 (44.5%). The expression levels of circulating miRNA-190 and -95 were determined by real time polymerase chain reaction with the 2-ΔΔct method. The diagnostic performance (sensitivity, specificity, and accuracy) of fine-needle aspiration cytology (FNAC), pmiRNA, and a combination of the two methods was correlated with the cytological and histological diagnoses.
RESULTS: The combination of pmiRNA and FNAC significantly increased the sensitivity (96.3%) with respect to each method alone (88.9% for FNAC and 89.6% for pmiRNA) by reducing the rate of false-negative results from 18 for FNAC and 17 for pmiRNA to only five. In patients in whom FNAC was not performed (n = 14) or in those with inadequate (n = 18) or indeterminate (n = 72) lesions submitted to surgery, pmiRNA correctly identified 90.8% of patients with benign disease and 74.3% of patients with cancer.
CONCLUSIONS: These results confirm that a combination of serum expression levels of miRNA-95 and -190 is an accurate and noninvasive tool for the differential diagnosis of thyroid nodules in the Italian population.

Entities:  

Keywords:  cancer; diagnosis; microRNA; nodules; thyroid

Mesh:

Substances:

Year:  2017        PMID: 28605303     DOI: 10.1089/thy.2017.0035

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma.

Authors:  Yanxia Jiang; Yajing Luan; Hong Chang; Guoan Chen
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

3.  Bioinformatics analysis of downstream circRNAs and miRNAs regulated by Runt-related transcription factor 1 in papillary thyroid carcinoma.

Authors:  Jiajie Xu; Guowan Zheng; Haiwei Guo; Kexin Meng; Wanchen Zhang; Ru He; Chuanming Zheng; Minghua Ge
Journal:  Gland Surg       Date:  2022-05

Review 4.  Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.

Authors:  Barbara Pardini; Alexandru Anton Sabo; Giovanni Birolo; George Adrian Calin
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

5.  Exosomal MicroRNA-374b-5p From Tubular Epithelial Cells Promoted M1 Macrophages Activation and Worsened Renal Ischemia/Reperfusion Injury.

Authors:  Chenguang Ding; Jin Zheng; Bo Wang; Yang Li; Heli Xiang; Meng Dou; Yuxi Qiao; Puxun Tian; Xiaoming Ding; Wujun Xue
Journal:  Front Cell Dev Biol       Date:  2020-11-26

6.  Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3η.

Authors:  Jiarui Liu; Yang Han; Shunfeng Hu; Yiqing Cai; Juan Yang; Shuai Ren; Yi Zhao; Tiange Lu; Xiangxiang Zhou; Xin Wang
Journal:  Front Cell Dev Biol       Date:  2021-04-27

Review 7.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.